MHRA

News

MHRA clears Moderna COVID vaccine for 12 to 17 year olds

The Moderna COVID-19 vaccine has become the second jab to be authorised for use in England, Scotland and Wales in children aged 12 to 17 after getting the nod from the Medicines and healthc

News

Merck's targeted lung cancer drug tepotinib wins early acces...

The UK drugs regulator has backed Merck KGaA's MET inhibitor for the treatment of some patients with non-small cell lung cancer under the early access to medicines scheme (EAMS).

News

MHRA grants bluebird 'innovation passport' for sickle cell t...

bluebird bio's sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an 'innovation passport' introduced in the UK earlier this year to speed up NHS access to promisi

News

Janssen J&J Johnson and Johnson pharmaceutical companies

Janssen COVID jab cleared in UK as fears of third wave mount

With concern already growing about a possible third wave of COVID-19 infections, the UK has cleared the use of a fourth vaccine from Johnson & Johnson's Janssen division.

News

UK will offer under-30s alternative to AZ's COVID jab

The UK drugs regulator has said people aged under 30 should be offered an alternative to the AstraZeneca COVID-19 vaccine, because of evidence linking it to rare blood clots.

News

Paediatric trial of AZ COVID jab 'halted as a precaution'

Oxford University has suspended a clinical trial of its AstraZeneca-partnered COVID-19 vaccine in children and adolescents while a possible link to rare cases of blood clotting is investiga

MHRA clears Moderna COVID vaccine for 12 to 17 year olds

Merck's targeted lung cancer drug tepotinib wins early acces...

MHRA grants bluebird 'innovation passport' for sickle cell t...

Janssen COVID jab cleared in UK as fears of third wave mount

UK will offer under-30s alternative to AZ's COVID jab

Paediatric trial of AZ COVID jab 'halted as a precaution'

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

MHRA

Editor's Picks